The 2025 market analysis identifies Oral Chemotherapy as the fastest-growing route of administration, now capturing over 56% of the market share. The convenience of at-home treatment and the development of "Sustained-Release" pills have led to high patient preference and improved adherence rates. Recent 2025 approvals, such as the oral tyrosine kinase inhibitor Zongertinib, offer alternative options for lung cancer patients who previously required weekly hospital-based IV infusions.

However, the shift to oral delivery introduces new challenges in "Bioavailability" and patient monitoring. Clinicians are increasingly utilizing Smart Pill Bottles and remote monitoring apps to track adherence in real-time. For a technical comparison of the pharmacokinetic profiles of oral vs. intravenous formulations, refer to the Chemotherapy Market industry analysis. This segment’s growth is also being fueled by "Online Pharmacies," which have expanded global access to life-saving medications.